Rydapt (midostaurin)

pCPA File Number: 21018
Negotiation Status:
Concluded with an LOI
Indication(s):
Acute Myeloid Leukemia (AML)
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0108-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: